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ABSTRACT  
 
Chemerin and its G protein-coupled receptor (ChemR23) have been associated with 
endothelial dysfunction, inflammation and insulin resistance. Whether chemerin directly 
influences insulin signaling in the vasculature is unknown. We hypothesized that chemerin 
impairs vascular insulin signaling in obesity-related type 2 diabetes, effect that would be 
improved by the novel ChemR23 antagonist (CCX 832). Molecular and vascular mechanisms 
were probed in mesenteric arteries and cultured vascular smooth muscle cells (VSMC) from 
C57BL/6, non-diabetic lean db/m and diabetic obese db/db mice as well as in human 
microvascular endothelial cells (HMEC). Chemerin decreased insulin-induced vasodilatation in 
C57BL/6 mice, effect prevented by CCX 832 treatment. In VSMC, chemerin, via oxidative 
stress- and ChemR23-dependent mechanisms, decreased insulin-induced IRS-1, PI3K and Akt 
phosphorylation, GLUT4 translocation to the membrane and glucose uptake. In HMEC, 
chemerin decreased insulin-activated nitric oxide signaling. AMPK phosphorylation was reduced 
in both HMEC and VSMC. CCX832 treatment of db/db mice decreased body weight, insulin and 
glucose levels and vascular oxidative stress. CCX832 also partially restored vascular insulin 
responses in db/db and high fat diet (HFD)-fed mice. Our novel in vivo findings highlight 
chemerin/ChemR23 as a promising new therapeutic target to limit insulin resistance and vascular 
complications associated with obesity-related diabetes. 
 
Keywords: Adipokines, insulin signaling, vascular smooth muscle and endothelial cells, type 2 
Diabetes. 
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INTRODUCTION 
 
Obesity, characterized by hypertrophy and hyperplasia of adipose tissue, is a critical risk 
factor for hypertension, dyslipidemia, cardiovascular disease, and type 2 diabetes (T2D) (1). The 
metabolic costs of obesity are also linked to decreased sensitivity to the biological actions of 
insulin, a condition identified as insulin resistance (2). In addition to its central energy storage 
function, adipose tissue secretes several bioactive hormones and cytokines, called adipokines (3). 
Adipokines have autocrine/paracrine effects that influence not only adipose tissue development 
and function (4), but also energy homeostasis, glucose and lipid metabolism, food intake, 
inflammation, and vascular function (3; 5). Dysregulation of adipokine production and secretion 
contribute to the pathogenesis of obesity and its associated vascular complications (3). 
Chemerin, also known as retinoic acid receptor responder protein 2 (RARRES2) or 
tazarotene-induced gene 2 protein (TIG2), is highly expressed in the placenta, liver, and white 
adipose tissue (WAT), with a lower expression in tissues such as lung, brown adipose tissue, 
heart, ovary, kidney, skeletal muscle and pancreas (6; 7). It is secreted as an 18-kDa inactive pro-
protein and undergoes extracellular serine protease cleavage to generate the 16-kDa active 
chemerin (8). Chemerin is a chemoattractant protein that binds to the G protein-coupled receptor 
CMKLR1 (chemokine-like receptor 1) or ChemR23, expressed in macrophages, dendritic cells, 
adipocytes (8) as well as in endothelial and vascular smooth muscle cells (VSMC), as recently 
reported (9). Although chemerin also activates the G protein-coupled receptor 1 (GPR1) with 
similar affinity to CMKLR1 (10) and is a ligand for a third receptor, chemokine receptor-like 2 
(CCRL2), which does not seem to activate intracellular responses (11), essentially all known 
responses to chemerin have been attributed to the activation of ChemR23. 
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Chemerin is currently described as a biomarker for adiposity in humans. Circulating 
chemerin levels were shown to be strongly associated with multiple components of metabolic 
syndrome, including body mass index (BMI), triglycerides, high-density lipoprotein cholesterol 
(HDL-C) and hypertension (7), and are also linked to adipogenesis (12; 13). Circulating 
chemerin levels are increased in numerous diseases associated with chronic inflammation (14). 
Serum levels of chemerin correlate with levels of proinflammatory cytokines, such as tumor 
necrosis factor (TNF-±), interleukin (IL-6) and C reactive protein (CRP) (14; 15). Importantly, 
ChemR23 knockout mice present reduced adiposity and body mass (16) and chemerin levels are 
reduced by weight loss and fat reduction (16). Chemerin expression is upregulated in adipocytes 
of diet-induced obese mice (13; 17). Increased chemerin expression in WAT, skeletal muscle, 
and liver has been reported in mouse models of obesity/diabetes and chemerin exacerbates 
glucose intolerance, lowers serum insulin levels, and decreases tissue glucose uptake in obese 
diabetic db/db mice (17).  
Although it has been reported that chemerin impairs insulin signaling and induces insulin 
resistance in skeletal muscle cells (18) and cardiomyocytes (19), the role of chemerin in vascular 
insulin resistance, i.e. whether chemerin affects vascular insulin signaling, has not been 
elucidated. Therefore, the present study aimed to determine whether chemerin influences 
vascular insulin signaling and whether there is interplay between chemerin/ChemR23, insulin 
resistance and vascular complications associated with T2D. We hypothesized that chemerin, 
through ChemR23, alters vascular insulin signaling and that ChemR23 antagonism attenuates 
abnormal vascular responses to insulin in obese diabetic db/db mice. 
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RESEARCH DESIGN AND METHODS 
 
Animals 
All experimental protocols were performed in accordance with the Ethical Principles in 
Animal Experimentation adopted by the Brazilian College of Animal Experimentation (COBEA) 
and were approved by the Ethics Committee on Animal Use (CEUA) of the University of Sao 
Paulo, Ribeirao Preto, Brazil and by the West of Scotland Research Ethics Service. Ten to twelve 
weeks-old male C57BL/6, lean non-diabetic db/m and obese diabetic db/db mice were housed in 
individually cages in a room with controlled humidity and temperature (22æC - 24æC), and 
light/dark cycles of 12 hours (h). Animals had free access to food and tap water. Animals were 
treated with vehicle (PEG400/cremophor) or CCX 832, a ChemR23 antagonist, (a gift from 
ChemoCentryx, Inc., Mountain View, CA, USA) (75 mg/kg/day, for 3 weeks, by oral gavage). 
Body weight was measured weekly from the beginning of the treatment. Animals were separated 
into 4 groups: db/m + vehicle, db/m + CCX 832, db/db + vehicle and db/db + CCX 832. In initial 
experiments, two additional groups were included: db/m and db/db mice without any treatment 
for the same three week-period, or untreated db/m and db/db mice, respectively. Since no 
difference was observed between untreated and vehicle groups, the remaining protocols were 
performed in animals treated with vehicle and CCX 832.  
In another set of experiments, six week-old male C57BL/6 mice were maintained either 
on a control diet (protein 22%, carbohydrate 70% and fat 8% of energy, PragSolucoes) or on a 
high-fat diet [(HFD), protein 10%, carbohydrate 25% and fat 65% of energy, PragSolucoes] for 
18 weeks. 
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Cultured Vascular Cells 
Vascular smooth muscle cells (VSMC) from mesenteric arteries of C57BL/6 mice were 
isolated and characterized as previously described (20). Subconfluent cell cultures were rendered 
quiescent by serum deprivation for 24 h before experimentation. Low-passage cells (passages 4–
6) from different primary cultures were used in our experiments.  
Human microvascular endothelial cells (HMEC) (Life Technologies, Carlsbad, CA, 
USA) were also studied. Endothelial cells were cultured in Medium 131 supplemented with 
Microvascular Growth Supplement (MVGS; 25 ml), Gentamicin (50 µg⁄ml) and Amphotericin B 
(0.25 µg⁄ml). For functional studies, confluent cells were quiescent for 4 hours in low-serum 
medium containing 0.5% FBS and subsequently stimulated according to the experimental 
protocol. When inhibitors were used in any protocol, parallel experiments were performed to 
determine the effects of the inhibitor itself. Data were only included in the graphics if the 
inhibitor by itself produced a significant effect.   
 
Chemerin and insulin levels  
Chemerin and insulin plasma levels were determined by ELISA, according to instructions 
from the manufactures (Cat. No. MCHM00 - R&D Systems and 10-1247-01 – Mercodia, 
respectively). 
 
Functional studies in mesenteric arteries  
Mesenteric arteries from C57BL/6, db/m and db/db mice, as well as from mice treated 
with a control or a HFD for 18 weeks, were cut into 2 mm ring segments and mounted in a wire 
myograph filled with 5 mL of physiological solution and continuously gassed with a mixture of 
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95% O2 and 5% CO2 at a temperature of 37º C. After 30 min of stabilization, the contractile 
ability of the preparations was assessed by adding KCl (120 mM) to the organ baths. Endothelial 
integrity was verified by relaxation induced by acetylcholine (1 µmol/L; ACh) in vessels pre-
contracted with phenylephrine (2 µmol/L; PhE). Concentration-effect curves to insulin were 
performed in arteries from all animal groups. In some experiments, the vascular preparations 
were incubated with Tiron (ROS scavenger, 100 µmol/L), CCX 832 (ChemR23 antagonist, 10 
nmol/L) or YS-49 (PI3K activator, 1 µmol/L). 
 
Immunoblotting 
Western blotting was developed in cultured VSMC from C57BL/6 and aorta from db/m 
and db/db mice treated with vehicle or CCX 832. Briefly, tissues were homogenized in lysis 
buffer [(in mmol/L) sodium pyrophosphate 50, NaF 50, NaCl 5, EDTA 5, EGTA 5, HEPES 10, 
Na3VO4 2, PMSF 50, Triton 100 0.5%, and leupeptin/aprotinin/pepstatin 1 mg/mL) and then 
sonicated for 5 sec. Proteins (50 – 60 µg) extracted from each lysate were separated by 
electrophoresis on SDS polyacrylamide gel, and transferred to a nitrocellulose membrane. 
Nonspecific binding sites were blocked with 5% milk in Tris-buffered saline solution with 
Tween (TBS-T) for one hour at room temperature. After incubation with secondary antibodies, 
signals were revealed with chemiluminescence, visualized by autoradiography and quantified 
densitometrically with open-source software ImageJ (http://imagej.nih.gov/ij/). Results were 
normalized by ² -actin, ±-tubulin or respective total proteins. Antibodies were used as follow: 
anti-eNOS [9572], anti-phospho eNOS [9571], anti-phospho Akt [9271], anti-Akt [9272], anti-
phospho PI3K [4228], anti-PI3K [4292], anti-phospho AMPK [2531], anti-AMPK [2532], anti-
phospho IRS1 [2384] and anti-IRS1 [2382] (Cell Signaling; 1:1000); anti-GLUT4 [07-1404] 
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(Millipore; 1:1000); anti- ±-tubulin [T6074] and anti- ² -actin [A2228] (Sigma; 1:10000). All 
primary antibodies were diluted in TBS-T 1% BSA and secondary antibodies only in TBS-T. 
 
Isolation of membrane and cytosolic fractions 
After stimulation, VSMC were treated with ice-cold hypotonic lysis buffer (10 mmol/l 
Tris, pH 7.4, 1.5 mmol/l MgCl2, 5 mmol/l KCl, 1 mmol/l DTT, 0.2 mmol/l sodium vanadate, 1 
mmol/l PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin). After passing the lysate through a 25-gauge 
syringe needle with several rapid strokes, the samples were centrifuged at 2000 g at 4°C for 5 
min. The supernatant was recentrifuged at 100,000 g at 4°C for 60 min. The pellet was 
resuspended in lysis buffer containing 0.1% Triton X-100 and served as the membrane fraction. 
Proteins were measured by the Bradford method using BSA as the standard. Membrane and 
cytosolic fractions were used to perform western blot analysis for GLUT4 translocation. 
 
Immunofluorescence 
Paraffin sections of aorta (4 µm) were deparaffinized in xylene, rehydrated through 
graded ethanol, and washed in water. All sections were incubated in EDTA (pH 8) and boiled for 
15 min at 95°C for antigen unmasking. Slides were cooled to room temperature, permeabilized 
in 0.5% Triton X-100 in PBS for 5 min, and blocked with 10% donkey serum, 1% BSA in 
1xTBS-T for one h at room temperature in a humidified chamber. For 8-hydroxyguanosine (8-
OHG) immunostaining, slides were incubated overnight with anti- 8-OHG goat polyclonal 
antibody (Abcam ab10802, 1:200) in a humidified chamber. Alexa-fluor-488-conjugated donkey 
anti-goat secondary antibody (Molecular probes, A-11055, 1:300) was used after primary 
antibody incubation for 1 h at room temperature in the dark. The slides were treated with 0.1% 
9 
 
Sudan Black B (Sigma Aldrich, 199664) in methanol for 10 min in order to remove lipofuscin-
mediated autofluorescence. Nuclei were counterstained with 4-6-diamidino-2-phenylindole 
(DAPI at 100 µg/ml) for 10 min. Sections were mounted with a coverslip using ProLong Gold 
anti-fade mounting media containing DAPI (Molecular probes, P-36931) in the dark. 
Fluorescence images were captured using Axiovert 200M microscope with a laser-scanning 
module LSM 510 (Carl Zeiss AG, Heidelberg, Germany). For negative controls, goat IgG-
matched isotype controls were used (Santa Cruz, sc-2028).   
 
Nitric oxide production 
Production of nitric oxide (NO) was determined with the NO fluorescent probe diacetate 
4-amino-5-methylamino-2’,7’-difluorofluorescein diacetate (DAF-2AM - Life Technologies, 
Carlsbad, CA, USA). Endothelial cells were incubated with DAF-FM diacetate (5 µmol/L, 30 
min) in serum free media, kept in the dark, and maintained at 37ºC. Cells were washed to remove 
excess probe and an additional incubation for 10 min was performed to allow complete de-
esterification of the intracellular diacetates. Cells were stimulated with chemerin (0.5 ng/mL) for 
one hour and insulin (100 nmol/L), CCX 832 (10 nmol/L), N-acetyl-cysteine (NAC; 10 µmol/L) 
and 740Y-P (PI3K/Akt signaling activator; 1 µmol/L) for 30 min. After stimulation, cells were 
washed with PBS and harvested by mild trypsinization (trypsin - 0.025%). Trypsin was 
inactivated with soybean trypsin inhibitor (0.025%) in PBS (1:1). Additional PBS (37ºC) was 
added to final volume of 10 mL. Cells were centrifuged for 3 min at 1200 rpm. Following 
centrifugation, the supernatant was discarded and the cell pellet reconstituted in PBS (250 µl). 
200 µl of the cell suspension was transferred to black 96 well microplates (Nunc® 436034). The 
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DAF-FM nitrosylation was assessed by a fluorimeter at excitation/emission wavelengths of 
495/515 nm. Fluorescence intensity was adjusted to protein concentration. 
 
Glucose uptake measurement  
VSMC were exposed to chemerin or vehicle, CCX 832, Tiron, AICAR (AMPK signaling 
activator; 1 mmol/L) or 740Y-P in the presence of insulin stimulation and then incubated with 
buffer Krebs-Ringer-Hepes (15 mmol/L Hepes [pH 7.4], 105 mmol/L NaCl, 5 mmol/L KCl, 1.4 
mmol/L CaCl2, 1 mmol/L KH2PO4, 1.4 mmol/L MgSO4 and 10 mmol/L NaHCO3) for 2 hours. 
The cells were incubated with insulin (100 nmol/L) for 30 min and 0.2 mmol/L glucose 2-deoxy-
D-glucose containing 1 µCi/ml of 2-deoxy-D- [3H] -glucose was added over 30 min. The buffer 
was rapidly removed, followed by three washes with ice-cold PBS. Cells were lysed with 500 µL 
of 0.4 mol/L NaOH for 5 min and neutralized with 500 µL of HCl. The amount of radiolabeled 
glucose associated with the lysed cells was determined by liquid scintillation counting. To 
control for changes in osmotic pressure, the effect of insulin on 14C-mannitol uptake was also 
determined. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad Software Inc., 
San Diego, CA, USA). Data are presented as means ± standard error of the mean (SEM). Groups 
were compared using student's t test or one-way analysis of variance (ANOVA). Bonferroni or 
Tukey's post-test were used as appropriate. Results of statistical tests with p < 0.05 were 
considered as significant. 
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RESULTS  
 
Chemerin decreases insulin-induced vasodilatation of mesenteric resistance arteries 
As shown in Figure 1A, chemerin decreased insulin-induced relaxation of mesenteric 
arteries from C57BL/6 mice, an effect blocked by the ChemR23 antagonist CCX 832 (Figure 
1B). An activator of PI3K signaling (YS-49) and a ROS scavenger (Tiron) reversed chemerin 
effects on insulin-induced vasodilatation (Figures 1C and 1D). 
 
Chemerin decreases insulin-induced NO signaling activation in endothelial cells. 
To verify whether chemerin affects NO signaling, HMEC were exposed to chemerin (0.5 
mg/ml) and probed for eNOS phosphorylation. Chemerin decreased basal and insulin-induced 
eNOS phosphorylation on the active site (Ser1177) (Figure 2A). These effects were attenuated 
both by a ROS scavenger (N-acetyl-l-cysteine – NAC) and a PI3K activator (740Y-P) (Figure 
2A), indicating that oxidative stress mechanisms and insulin-downstream signaling are involved 
in chemerin-induced decrease in NO bioavailability, leading to endothelial dysfunction.   
To determine whether reduced eNOS phosphorylation was associated with decreased NO 
production, levels of NO were estimated in insulin-stimulated HMEC. Insulin increased NO 
levels in HMEC and chemerin significantly decreased insulin-induced NO production. This 
effect involves ChemR23-, PI3K signaling- and ROS-dependent mechanisms since CCX 832, 
740Y-P and NAC partially inhibited chemerin effects (Figure 2B). 
 
Chemerin decreases vascular insulin signaling in VSMC. 
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In addition to its effects on endothelial cells, chemerin decreased insulin signaling in 
VSMC. Insulin increased IRS-1 phosphorylation in VSMC, which is reduced by simultaneous 
treatment with chemerin. Chemerin effects rely on ROS formation, but not on ChemR23 
activation (Figure 3A). Insulin increased PI3K and Akt phosphorylation in VSMC and chemerin 
decreased insulin-induced PI3K/Akt phosphorylation via ChemR23 and ROS-dependent 
mechanisms (Figures 3B and 3C).  
To further investigate chemerin effects on insulin signaling, GLUT4 translocation from 
the cytosol to the membrane was determined. In VSMC, chemerin decreased insulin-induced 
GLUT4 translocation to the membrane (Figure 3D). This was blocked by CCX 832 and 740Y-P 
(Figure 3D) suggesting that ChemR23 and PI3K activation contribute to chemerin effects on 
GLUT4 translocation in VSMC.  
 
Chemerin reduces insulin-stimulated glucose uptake in VSMC 
We evaluated the effects of chemerin on AMPK phosphorylation, another mechanism for 
glucose uptake. Chemerin decreased AMPK phosphorylation (Thr172) both in VSMC and HMEC 
(Figures 3E and 3F). To evaluate whether chemerin also affects insulin-induced glucose uptake, 
2-deoxyglucose uptake was measured in VSMC exposed to 2 µCi/ml 2-[3H]DG in the presence 
of unlabeled 2-DG. In VSMC, chemerin decreased insulin-induced glucose uptake (Figure 4) 
through ROS generation, AMPK and PI3K/Akt signaling since Tiron, AICAR and 740Y-P 
reversed the effects of chemerin on glucose transport (Figure 4). 
 
ChemR23 antagonism decreases body weight and insulin and glucose levels in db/db mice 
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Since chemerin influences vascular insulin signaling, we investigated whether ChemR23 
antagonism attenuates diabetes-related vascular dysfunction and insulin resistance. Plasma 
chemerin levels were significantly increased in diabetic obese db/db mice (Figure 5A). CCX 832 
treatment slightly reduced body weight of db/db mice when compared to vehicle-treated db/db 
mice (Figure 5B). In addition, CCX-treated db/db mice exhibited decreased plasma levels of 
glucose and insulin vs vehicle-treated db/db mice (Figures 5C and 5D). 
 
CCX 832 partially reverses vascular insulin dysfunction in vessels from db/db mice 
As shown in Figure 6A, insulin-induced dilation was decreased in mesenteric arteries 
from vehicle-treated db/db mice vs. vehicle-treated db/m mice. CCX 832 treatment partially 
improved insulin-induced vasodilation in db/db mice (Figure 6A). Moreover, IRS-1 (Ser302), 
PI3K (Tyr458/Thr199) and Akt (Ser473) phosphorylation were reduced in aorta from vehicle-treated 
db/db mice vs. vehicle-treated db/m mice and CCX 832-treated db/db mice (Fig. 6B-D), 
indicating beneficial effects of in vivo treatment with CCX 832 on insulin signaling. 
Additionally, as observed in Figure 7A, increased levels of chemerin were also observed 
in HFD-fed mice. The ChemR23 antagonist CCX 832 attenuated impaired insulin-induced 
dilatation in mesenteric arteries from HFD-treated mice (Figure 7B). 
 
CCX 832 reduces vascular oxidative stress in db/db mice 
Considering that chemerin increases ROS generation (21) and that oxidative stress 
accounted for most of the effects of chemerin upon vascular insulin signaling, we investigated 
whether ChemR23 antagonist attenuates ROS generation in db/db mice. Db/db mice presented 
increased vascular levels of ROS in comparison to vehicle- and CCX 832-treated db/m mice 
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(Figures 8A and 8B). This was reduced by treatment of db/db mice with CCX 832 (Figures 8A 
and 8B). 
 
DISCUSSION 
Our results demonstrated that (1) chemerin decreases insulin-induced vasodilation by 
mechanisms involving ChemR23 activation, disruption of PI3K/Akt signaling and oxidative 
stress; (2) chemerin decreases insulin-induced eNOS phosphorylation and NO production in 
endothelial cells through mechanisms that affect PI3K/Akt signaling and ROS generation; (3) 
chemerin decreases activation of insulin signaling pathways via ChemR23 and oxidative stress in 
VSMC; (4) ChemR23 antagonism with CCX 832 decreases glucose and insulin levels in db/db 
mice; (5) CCX 832 partially restores insulin-induced vasodilatation and improves insulin 
signaling in diabetic obese mice; (6) CCX 832 decreases vascular oxidative stress in db/db mice. 
These novel findings show that the chemerin/ChemR23 axis plays a critical role in diabetes-
associated vascular oxidative stress and altered insulin signaling. 
In obesity, production of adipokines triggers chronic inflammation and leads to increased 
levels of proinflammatory cytokines (22), which can modify insulin signaling. Tumor necrosis 
factor-alpha (TNF-±) and interleukin-6 (IL-6), for example, are good predictors of the 
development of T2D (23). TNF-± has been identified as a regulator of insulin sensitivity (24). In 
3T3-L1 adipocytes, IL-6 reduces expression of insulin receptor substrate (IRS-1) and the glucose 
transporter GLUT4 (25). Similarly, increased levels of TNF-± reduce IRS-1 phosphorylation and 
decrease insulin signal transduction in skeletal muscle and adipose tissue from obese rats (26). 
Accordingly, our data show that chemerin, a pro-inflammatory adipokine, decreases insulin-
induced phosphorylation of IRS-1, PI3K and Akt as well as reduces GLUT4 translocation to the 
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membrane and insulin-induced glucose uptake in VSMC from control mice. Molecular effects of 
chemerin in vascular insulin signaling are associated with a decrease in insulin-induced 
vasodilation, by mechanisms that affect PI3K/Akt signaling and oxidative status. Together, these 
findings suggest that the adipokine chemerin confers an insulin resistant phenotype to VSMC.  
Corroborating our data, a recent study demonstrated that chemerin decreases glucose 
uptake and Akt phosphorylation in insulin-stimulated cardiomyocytes (19). Inhibition of ERK1/2 
MAPK partially prevented chemerin-induced impairment of Akt phosphorylation and glucose 
uptake (19). In addition, Jager and colleagues have shown that IL-1²  reduces insulin-induced 
PI3K/p85 and Akt phosphorylation (Thr308) (27). Similarly, IL-1²  decreases IRS-1 and Akt 
protein expression in adipocytes, which leads to lower insulin-induced glucose uptake (27).  
Furthermore, db/db mice treated with ChemR23 antagonist (CCX 832) present a slight 
decrease in body weight, supporting the suggestion that chemerin regulates adipogenesis via 
ChemR23 receptor (28). However, the effects of depletion or inhibition of ChemR23 upon body 
weight are still controversial. While Rouger et al did not observe changes in body weight or fat 
mass in ChemR23 knockout (KO) mice (29), Ernst and colleagues showed that CMKLR1-/- mice 
have lower food intake, total body mass, and percent of body fat compared with wild-type 
controls (16).  
In addition to considering chemerin effects on body weight, it is important to consider 
metabolic aspects, such as glucose and insulin levels. CCX 832-treated db/db mice exhibited a 
significant decrease in plasma glucose and insulin levels, strengthening the notion that chemerin 
contributes to insulin resistance in this model of obesity related to T2D. Of importance, 
significant increased levels of chemerin were observed both in db/db and HFD-treated mice, 
reinforcing the idea that this adipokine is linked to glucose homeostasis and metabolic disorders 
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in obesity and T2D (17). Ernst and colleagues demonstrated that CMKLR1-/- mice fed with high 
fat diet present reduced blood glucose and serum insulin. However, CMKLR1 loss is associated 
with glucose intolerance, which was linked to decreased glucose-stimulated insulin secretion 
(16). On the other hand, Rouger and colleagues verified that glucose tolerance was not affected 
in young ChemR23 knockout mice (29).  
Classically, insulin metabolic signaling results in vasodilatation via increased NO 
production and production of prostaglandins and endothelium-derived hyperpolarizing factors 
(30). In addition to reducing insulin-induced vasodilatation in non-obese mice by mechanisms 
involving PI3K/Akt pathway and oxidative stress, chemerin also reduces eNOS phosphorylation 
(Ser1177) and decreases insulin-stimulated NO production in endothelial cells, also by oxidative 
stress-mediated events. These effects of chemerin may be directly involved in vascular insulin 
dysfunction associated with diabetes and obesity. It has been proposed that resistance to the 
vascular effects of insulin selectively involves the PI3K/Akt/NO signaling pathway (31). In 
endothelial cells, blockade of the PI3K pathway induces insulin resistance, which in turn blunts 
production of NO (32). As demonstrated in this study, most of chemerin effects are mediated by 
ChemR23 since its antagonism partially restores the decreased insulin-induced vasodilatation in 
both obesity models, db/db and HFD-fed mice and also chemerin increases vascular PI3K, Akt 
and IRS-1 phosphorylation in db/db mice.  
Oxidative stress contributes to insulin resistance, particularly in skeletal muscle as well as 
dysfunction of pancreatic ²  cells (33). Cellular and systemic disorders that may contribute to 
overproduction of reactive oxygen species (ROS), including hyperglycemia, dyslipidemia, 
endoplasmic reticulum (ER) stress, advanced glycation end products (AGEs), nitric oxide 
synthase and lipid peroxides, can activate factors associated with insulin resistance (34). In 
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humans, there is a positive association between serum markers of oxidative stress and the degree 
of insulin resistance (35). In experimental animal models, oxidative stress interrupts IRS-1 and 
PI3K activation induced by insulin, and impairs the translocation of GLUT4 in 3T3-L1 
adipocytes (36). In adipose tissue from healthy men with excessive caloric intake, oxidative 
stress induces insulin resistance partially via carbonylation and oxidation-induced inactivation of 
GLUT4 (37). Hence, increased ROS generation in vessels from db/db mice may be associated 
with decreased insulin signaling observed in those animals. In addition, chemerin/ChemR23 axis 
may contribute to insulin resistance since ChemR23 antagonism attenuates ROS generation and 
also restores insulin signaling in vessels from db/db mice. Furthermore, our findings clearly 
show the involvement of oxidative stress upon chemerin-induced insulin signaling impairment 
since antioxidants attenuate the reduced Akt and IRS-1 phosphorylation as well as the decreased 
glucose uptake and insulin-induced vasodilatation observed in VSMC and arteries challenged 
with chemerin.   
This study also demonstrates that chemerin decreases AMPK phosphorylation both in EC 
and VSMC. AMPK is a serine-threonine kinase that has emerged as an important mediator of 
glucose metabolism (38) and AMPK-activating drugs are potentially useful in T2D treatment. It 
is already established that acute AMPK activation stimulates glucose uptake by skeletal muscle 
via both GLUT1 and GLUT4 (39). In cardiomyocytes, AMPK activation increases GLUT4 
expression in a PKC-dependent manner (40). Moreover, AMPK activation by 5-amino-4-
imidazole-1-² -D-carboxamide ribofuranoside (AICAR) increases heart and skeletal muscle 
glucose uptake (41; 42) possibly by increasing GLUT4 expression (43). Most importantly, 
overexpression of human GLUT4 gene protects db/db mice from insulin resistance and diabetes 
(44). Similarly, our findings show that AICAR (and also PI3K/Akt activation) reverses the 
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effects of chemerin on insulin-induced glucose uptake in VSMC from normal mice, in 
accordance with the diminished AMPK phosphorylation in response to chemerin. 
Crosstalk between GPCRs and tyrosine kinase receptors (RTKs) is increasingly being 
recognized as a major mechanism regulating complex signaling pathways (45) . ChemR23 is an 
orphan G protein-coupled receptor that acts through Gi to activate various intracellular signaling 
pathways, such as ERK1/2 (46). The insulin receptor (IR) belongs to the family of RTKs, which 
play a critical role in development, cell division, and metabolism (47). Activation of RTK family 
members results in autophosphorylation and phosphorylation of selective protein substrates 
(IRS) exclusively on tyrosine residues (48). Recently, various likely mechanisms for the 
transactivation between GPCR and RTK have emerged. Molecules such as PKC, Src and ROS as 
well as adaptor/scaffold proteins such as Gab1, IRS-1, and GIT1 have been implicated as 
mediators of GPCR-ligand induced RTK transactivation. Protein tyrosine phosphatases have also 
been implicated in GPCR–RTK crosstalk (49). This study shows that chemerin, through 
ChemR23, modulates IRS-1 phosphorylation and the subsequent signaling cascade. Recently, 
chemerin has been shown to stimulate bone marrow-derived mesenchymal stromal cells 
migration via p42/44, p38 and JNK-II kinases in a PKC-dependent manner (50). A limitation of 
the present study is that mechanisms underlying ChemR23 and IR/IRS crosstalk have not been 
explored. Thus, further studies are needed to understand and dissect specific proteins linking 
ChemR23 and IR/IRS signaling.   
In conclusion, our data indicate that the chemerin/ChemR23 system plays an important 
role in diabetes-associated impaired vascular insulin signaling and oxidative stress, suggesting its 
involvement in the pathogenesis of vascular insulin resistance. Antagonism of the system 
ameliorates vascular dysfunction and normalizes insulin signaling. Targeting 
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chemerin/ChemR23 may be an attractive strategy to improve insulin signaling and vascular 
function in obesity-associated diabetes.  
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LEGENDS TO FIGURES 
 
Figure 1. Chemerin decreases insulin-induced vasodilatation via ChemR23, PI3K/Akt and 
oxidative stress-dependent mechanisms. Endothelium-intact mesenteric resistance arteries 
from C57BL/6 mice were incubated with chemerin (0.5 ng/mL) or vehicle for one hour. 
Relaxation response of PhE-contracted vessels to insulin was evaluated in the absence (A) and in 
the presence of (B) CCX 832 (ChemR23 antagonist), (C) YS-49 (PI3K activator) or (D) Tiron 
(ROS scavenger), which were added 30 min before the vehicle or chemerin. Results represent the 
mean ± SEM of 5 to 6 experiments. * p<0.05 vs. vehicle; # p<0.05 vs. chemerin. 
 
Figure 2. Chemerin decreases insulin-induced NO signaling activation in endothelial cells. 
(A) Phosphorylation of the activation site of eNOS (Ser1177) was determined by western blot in 
endothelial cells stimulated with chemerin (0.5 ng/mL, one hour) and insulin (30 min) in the 
absence or presence of CCX 832 (ChemR23 antagonist), NAC (ROS scavenger) or 740Y-P 
(PI3K activator). Values were normalized by total NOS expression. (B) Nitric oxide (NO) 
production was determined by DAF2-DA fluorescence in endothelial cells and values were 
normalized by protein amount. Bars represent the mean ± SEM of 5 to 6 experiments. * p<0.05 
vs. vehicle, Ã vs. insulin, Æ vs. chemerin + insulin. 
 
Figure 3. Chemerin decreases vascular insulin signaling in VSMC. Phosphorylation of IRS-1 (A), 
PI3K (B), Akt (C), GLUT4 translocation to the membrane (D),  phosphorylation of AMPK in VSMC 
(E) and HMEC (F) were determined by western blot. Cells were pre-treated with CCX 832 
(ChemR23 antagonist), NAC (ROS scavenger) or 740Y-P (PI3K activator), 30 min before the 
stimulation with chemerin and/or insulin. VSMC and HMEC were stimulated with chemerin (0.5 
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ng/mL, one hour). Values were normalized by expression of total protein or α-tubulin. To keep 
the same sequence of experimental groups for all graphs, representative western blotting 
figures for Akt were spliced as observed in figure 3C. Bars represent the mean ± SEM of 5 to 6 
experiments. * p<0.05 vs. vehicle; # p<0.05 vs. chemerin, σ p<0.05 vs. insulin, φ p<0.05 vs. 
chemerin + insulin. 
 
Figure 4. Chemerin reduces insulin-stimulated glucose uptake in VSMC. 2-Deoxyglucose 
(2-DG) uptake was measured by exposing VSMC to 2 µCi/ml 2-[3H]DG in the presence of 
unlabeled 2-DG. Cells were stimulated with chemerin, CCX 832 (ChemR23 antagonist), Tiron 
(ROS scavenger), AICAR (AMPK activator) and 740Y-P (PI3K activator) 30 min prior to the 
incubation with insulin and measurement of 2-DG uptake was then determined. Values represent 
the mean ± SEM of 5 to 6 experiments. * p<0.05 vs. vehicle, # p<0.05 vs. chemerin. 
 
Figure 5. ChemR23 antagonism decreases body weight and insulin and glucose levels in 
db/db mice. (A) Plasma levels of chemerin were measured by Elisa in db/m and db/db mice. (B) 
Body weight of untreated, vehicle-treated and CCX 832-treated db/m and db/db mice was 
measured along three weeks of treatment. Glucose (C) and insulin (D) levels in vehicle- and 
CCX 832-treated db/m and db/db mice. Values represent the mean ± SEM of 5 to 8 experiments. 
* p<0.05 vs. db/m, •  p<0.05 vs. db/db vehicle. 
 
Figure 6. CCX 832 partially reverses vascular insulin dysfunction in db/db mice. 
Concentration-effect curves to insulin (A) were performed in PhE-contracted mesenteric arteries 
from vehicle- and CCX 832-treated db/m and db/db mice. Phosphorylation of IRS-1 (B), PI3K 
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(C) and Akt (D) in aorta from vehicle and CCX 832-treated db/m and db/db mice was 
determined by western blot. Values were normalized by total protein expression. Results 
represent the mean ± SEM of 5 to 8 experiments. * p<0.05 vs. db/m, •  p<0.05 vs. db/db vehicle. 
 
Figure 7. CCX 832 attenuates vascular insulin dysfunction in HFD-fed mice. (A) Serum 
levels of chemerin were measured by Elisa in mice fed a control or a HFD. (B) Concentration-
effect curves to insulin were performed in PhE-contracted mesenteric arteries from control diet- 
and HFD-treated mice. Curves were performed in the presence and absence of CCX 832 
(ChemR23 antagonist). Results represent the mean ± SEM of 5 experiments. ô  p<0.05 vs. control 
diet, † p<0.05 vs. HFD. 
 
Figure 8. CCX 832 reduces vascular oxidative stress in db/db mice. (A) Representative 
images and (B) quantitative analysis of 8-OHG-positive nuclei in endothelium-intact aorta from 
vehicle and CCX 832-treated db/m and db/db mice. Scale bar = 50 µm; 20X. Results represent 
the mean ± SEM of 5 to 8 experiments. * p<0.05 vs. db/m, •  p<0.05 vs. db/db vehicle. 
 
